Sintx Technologies, Inc.

Listed Company

SINTCIK 0001269026NasdaqNon-AcceleratedSmaller ReportingSurgical & Medical Instruments & ApparatusDelawareFY ends Dec 31

Period

FY 2025

Revenue

$1.02M

Net Income

$-10.36M

Total Assets

$9.51M

Equity

$2.93M

Shares Out

4.12M

Op. Cash Flow

$-8.57M

Business

SINTX Technologies is an advanced ceramics company that develops and manufactures silicon nitride‑based biomedical and antipathogenic solutions. It produces silicon nitride powders, solid and porous components, composites with PEEK/PEKK, and thin coatings for use in medical implants, composites, coatings and antipathogenic products. Its business focuses on biomedical applications (spinal fusion, arthroplasty, dental, foot & ankle, maxillofacial), antipathogenic applications (masks, filters, wound care) and materials R&D including AI‑designed 3D printing. Products are supplied through direct manufacturing, OEM partnerships and collaborations with surgeons, hospitals and international distributors in the U.S., Europe, Asia and South America.

Summary from filing dated 2025-03-19

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenue	1	3	3	2	606,000
Cost of revenue	557,000	811,000	784,000	265,000	449,000
Gross profit	461,000	2	2	1	157,000
Research and development	5	5	9	6	6
General and administrative	6	4	4	4	4
Sales and marketing	242,000	614,000	1	1	1
Armor exit costs	—	5	—	—	—
Reduction in force	—	407,000	—	—	—
Grant and contract expenses	156,000	1	—	—	—
Total operating expenses	11	16	15	13	11
Loss from operations	−11	−14	−13	−11	−11
Interest expense	−52,000	−29,000	−2,000	−17,000	−25,000
Interest income	175,000	107,000	135,000	23,000	101,000
Gain (loss) on the disposal of assets	327,000	−19,000	17,000	−1,000	144,000
Change in fair value of derivative liabilities	−124,000	3	6	−1	—
Offering costs of derivative liabilities	—	−550,000	−786,000	—	—
Other income (expense)	31,000	39,000	17,000	382,000	4,000
Total other income (expense), net	357,000	3	5	−704,000	1
Net loss before income taxes	−10	−11	−8	−12	−9
Provision for income taxes	—	—	—	—	—
Net loss	−10	−11	−8	−12	−9
Deemed dividend related to warrant inducement	−7	—	—	—	—
Net loss attributable to common stockholders	−17	−11	−8	−16	−9
Basic net loss	−3.74	−14.87	−442.08	−39.92	—
Basic deemed dividend related to warrant inducement	−2.42	—	—	—	—
Basic attributable to common stockholders	−6.16	−14.87	−443.47	−54.67	−37.7
Diluted net loss	−3.74	−15.19	−623.28	−46.79	—
Diluted - deemed dividend related to warrant inducement	−2.42	—	—	—	—
Diluted attributable to common stockholders	−6.16	−15.19	−624.47	−60.81	−39.91
Basic	3	741,250	18,682	301,610	246,919
Diluted	3	744,782	21,786	317,323	250,701

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	4	4	3	6	14
Account and other receivables, net of allowance totaling $2.4 and $61.0 respectively	178,000	196,000	685,000	328,000	102,000
Prepaid expenses and other current assets	507,000	225,000	539,000	344,000	350,000
Inventories	825,000	502,000	888,000	—	—
Total current assets	6	5	6	7	15
Inventories, net	219,000	465,000	333,000	453,000	294,000
Property and equipment, net	476,000	922,000	5	6	4
Intangible assets, net	142,000	16,000	21,000	26,000	31,000
Goodwill	302,000	—	—	—	—
Operating lease right of use asset	3	3	4	2	2
Other long-term assets	259,000	330,000	559,000	85,000	77,000
Total assets	10	9	15	16	22
Accounts payable	382,000	299,000	636,000	434,000	241,000
Accrued liabilities	422,000	986,000	1	2	1
Debt	7,000	32,000	46,000	160,000	509,000
Derivative liabilities	827,000	208,000	304,000	5	347,000
Current portion of operating lease liability	398,000	456,000	512,000	738,000	500,000
Other current liabilities	2	1,000	4,000	2,000	—
Total current liabilities	4	2	3	8	3
Operating lease liability, net of current portion	3	4	4	2	2
Total liabilities	7	6	7	10	5
Commitments and contingencies	—	—	—	—	—
Treasury stock, 50,424 shares as of December 31, 2025	−133,000	—	—	—	—
Common stock, $0.01 par value, 250,000,000 shares authorized; 3,970,869 and 1,342,853 shares issued and outstanding as of December 31, 2025 and 2024, respectively.	40,000	13,000	—	5,000	2,000
Additional paid-in capital	295	286	279	268	268
Accumulated deficit	−292	−282	−271	−263	−250
Total stockholders equity	3	4	9	6	17
Total liabilities and stockholders equity	10	9	15	16	22

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation expense	300,000	800,000	900,000	300,000	200,000
Amortization of right of use asset	324,000	537,000	745,000	623,000	—
Amortization of intangible assets	19,000	5,000	5,000	5,000	5,000
Loss on disposal of subsidiary	25,000	—	—	—	—
Impairment of Armor	64,000	5	—	—	—
Stock based compensation Employee	1	82,000	291,000	369,000	309,000
Stock based compensation Non-employee	606,000	—	—	—	—
Change in fair value of derivative liabilities	124,000	−3	−6	1	—
Loss (gain) on disposal of equipment	−352,000	18,000	−17,000	1,000	−144,000
Bad debt expense (recoveries)	−3,000	−1,000	—	−7,000	—
Account and other receivables	−69,000	490,000	−420,000	−26,000	−61,000
Prepaid expenses and other assets	−47,000	482,000	−264,000	13,000	−149,000
Inventories	−85,000	72,000	−485,000	−140,000	−110,000
Accounts payable and accrued liabilities	−200,000	−756,000	−12,000	226,000	264,000
Other liabilities	45,000	−2,000	−370,000	−128,000	−26,000
Payments on operating lease liability	−367,000	−514,000	−689,000	−586,000	−401,000
Net cash used in operating activities	−9	−9	−14	−10	−10
Purchase of property and equipment	−185,000	−690,000	−530,000	−1	−4
Disposal of property and equipment, net of cash received	−4,000	—	—	—	—
Proceeds from the sale of property and equipment	352,000	20,000	29,000	1,000	144,000
Proceeds from acquisition of Sinaptic Surgical	750,000	—	—	—	—
Proceeds from notes receivable, net of imputed interest	—	476,000	—	—	—
Net cash provided by (used in) investing activities	913,000	−194,000	−501,000	−1	−2
Proceeds from issuance of warrant derivative liabilities	—	3	7	—	—
Proceeds from issuance of common stock and prefunded warrants, net of cash fees	4	6	5	—	—
Proceeds from exercise of warrants, net of cash fees, and deposit for stock issuance (in other current liabilities)	4	—	—	—	—
Proceeds from issuance of common stock in connection with ATM, net of fees	329,000	—	—	—	—
Proceeds from issuance of warrants in connection with exercise of warrants	206,000	—	—	—	196,000
Purchase of common stock into treasury	−133,000	—	—	—	—
Proceeds from issuance of common stock in connection with exercise of warrants	—	2,000	—	—	—
Principal payment on debt	−206,000	−349,000	−114,000	−509,000	—
Net cash provided by financing activities	8	9	12	3	705,000
Net increase in cash and cash equivalents	542,000	258,000	−3	−8	−11
Reduction of derivative liability upon exercise of warrants	—	1,000	6	—	—
Deemed dividend related to warrant inducement and issuance of warrants	7	—	—	—	—
Right of use asset for amended lease liability decrease	—	307,000	−89,000	—	—
Debt issued for prepaid insurance	180,000	335,000	—	—	—
Agent warrant offering cost allocated to equity	—	13,000	—	—	—
Cash paid for interest	52,000	29,000	21,000	1,000	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro